The findings suggest that PD-L1 may be a promising therapeutic target, even in the absence of significant grade-specific trends by demonstrating PD-L1 presence in the majority of glioma cases, highlighting its potential as a therapeutic target in GBM immunotherapy. Here, CD274 is linked to glioblastoma.